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Background: To measure the uptake of first invitation to cervical screening by vaccine status in a population-based cohort offered
HPV immunisation in a national catch-up campaign.
Methods: A retrospective observational study of routinely collected data from the Scottish Cervical Screening Programme.
Data were extracted and linked from the Scottish Cervical Call Recall System, the Scottish Population Register and the Scottish
Index of Multiple Deprivation. Records from 201 023 women born between 1 January 1988 and 30 September 1993 were assessed.
Women born in or after 1990 were eligible for the national catch-up programme of HPV immunisation. Attendance for screening
was within 12 months of the first invitation at age 20 years.
Results: There was a significant decline in overall attendance from the 1988 cohort to the 1993 cohort with the adjusted
attendance ratio of the 1988 cohort being 1.49 times (95% CI 1.46–1.52) that of the 1993 cohort. Immunisation compensated for
this decrease in uptake with unvaccinated individuals having a reduced ratio of attendance compared with those fully vaccinated
(RR¼ 0.65, 95% CI 0.64–0.65). Not taking up the opportunity for HPV immunisation was associated with an attendance for
screening below the trend line for all women before the availability of HPV immunisation.
Conclusions: HPV immunisation is not associated with the reduced attendance for screening that had been feared. Immunised
women in the catch-up cohorts appear to be more motivated to attend than unimmunised women, but this may be a result of a
greater awareness of health issues. These results, while reassuring, may not be reproduced in routinely immunised women.
Continued monitoring of attendance for the first smear and subsequent routine smears is needed.
Countries with organised cytology-based cervical screening
programmes have shown a considerable decrease in the incidence
of cervical cancer. Data from the United Kingdom and the
Republic of Ireland demonstrate the temporal relationship between
the central organisation of cervical screening in 1988 and the
subsequent decrease in the incidence of invasive cervical carcinoma
(Comber and Gavin, 2004). In Scotland, women are currently
screened between the ages of 20 and 60 years. Uptake over 5.5
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years for the years 2013–2014 was 77.3% overall, with 53.8% for
those aged 20–24 years (www.isdscotland.org/health-topics/cancer/
cervicalscreening/).
Uptake of cervical screening is affected by a number of factors,
including deprivation, accessibility and acceptability of the test,
educational attainment and information about cervical cancer and
hence perception of risk (Waller et al, 2009; Everett et al, 2011;
Waller et al, 2012). Uptake is improved by a systematic approach
to call and recall of women. There is a concern that women who
have been vaccinated against HPV perceive themselves to be at low
risk of developing cervical cancer and hence do not attend
for screening when invited (Price et al, 2011; Paynter et al, 2015).
Low uptake rates will make the screening programme increasingly
ineffective, no matter which test is used and affect the benefits
anticipated from vaccination.
Continued attendance for cervical screening is important for
many reasons. The HPV types employed in the two vaccines
currently account for B75% of cancers, depending upon the
population. Cross-protection for HPV 31, 33 and 45 would
increase the percentage of tumours potentially covered to between
75 and 80% (Smith et al, 2007; Cuschieri et al, 2010). However, this
leaves between 20 and 25% of tumours for which regular screening
is still the only prevention. The duration of immunity is thought to
be extensive on the basis of serological- and population-based
studies, and there is emerging evidence of herd protection in
countries with high uptake of vaccine (Tabrizi et al, 2014; Drolet
et al, 2015; Cameron et al, 2016). There are, however, still several
areas that require to be elucidated, including the effect of HPV
immunisation at a population level in the long-term and possible
HPV genotype replacement. Although preliminary population-
based data suggest that type replacement may not be important
clinically, at least in the short-term, there is a need for continued
surveillance of both immunised and non-immunised women, for
which adequate attendance at screening is required (Kavanagh
et al, 2014).
Scotland both screens from an early age (currently age 20 years)
and has a highly organised and effective school-based immunisa-
tion programme. Uptake of vaccine in the catch-up cohorts (catch-
up programme ran from September 2008 to end of 2011 and
targeted girls from their 13th birthday until their 18th birthday)
was 65% overall, varying between 40% in school leavers and 80% in
those still at school (Information Services Division, 2012). Routine
immunisation in school at age 12–13 years continues to achieve
490% uptake of all three doses (Information Services Division,
2014). In addition, Scotland has the advantage of direct linkage
between immunisation status and cervical screening data through
the use of a unique personal identifier, the Community Health
Index (CHI) number that is used on all health-care systems and
records (Bhopal et al, 2012). It enables linkage of a wide variety of
systems, allowing correlation of health interventions with disease
and a variety of socio-economic and demographic factors. This
enables direct examination of the effects of HPV immunisation on
several aspects of service delivery. In this paper, we quantify the
association between the uptake of first invitation to cervical
screening with the uptake of HPV vaccination in the catch-up
programme.
METHODS
Data selection and extraction. The Scottish Cervical Call Recall
System (SCCRS) is a nationwide, population register-based
computer system, populated with demographic data from the
population register, in use since 2007 whose function is to manage
all aspects of call and recall. It incorporates immunisation status,
acts as a requesting and reporting system for cytology and records
relevant histology and HPV results. It includes in its reports
recommended management and refers women directly for
colposcopy. The dates of screening invitations and reminders are
recorded, as are the reasons for exclusion from screening—for
example, pregnancy, no cervix, severe inter-current illness or a
formal declaration to opt out. Invitations are sent to all eligible
women at their current recorded address by GP registration.
The screening attendance of all women born between 1 January
1988 and 30 September 1993 in the year after their 20th birthday
was obtained from SCCRS. This was based upon an extract in Q1
2015 that had validated data up to the end of Q3 2014.
Consequently, the 1993 birth cohort is truncated to ensure this
cohort has at least 12 months follow-up. The information included:
 date invited for screening,
 date attended/reminded/defaulted as appropriate,
 if excluded from screening, and reason for exclusion,
 CHI,
 postcode of current residence recorded by registered general
practitioner,
 number of doses of vaccine administered.
Women in the data set were classified as those eligible for the
catch-up vaccination campaign and those not (those born before
September 1990) according to their date of birth.
Data linkage. The CHI registry data set was used to identify the
population in SCCRS that were resident in Scotland at age 20 years
and to eliminate any duplicate CHI records created in error, to
record attendance for the same individual. Once duplicate records
had been merged with retention of relevant data, women with
legitimate exclusions were removed in order to obtain an accurate
denominator for the eligible population. These exclusions included
‘Not clinically appropriate’, death, transferred out of Scotland, and
temporarily excluded for a co-morbidity or for being pregnant.
The postcode of residence was used to generate a deprivation
code (Scottish Index of Multiple Deprivation SIMD 2012 version),
and indices of rurality (Scottish Government Scottish Index of
Multiple Deprivation http://www.scotland.gov.uk/Topics/Statistics/
SIMD) Deprivation is divided into quintiles, with SIMD1 being the
most deprived and SIMD5 being the least deprived. Rurality is
divided into three categories, urban (population of 410 000),
accessible remote (30–60min travel time from an urban centre)
and very remote (460min travel time from an urban centre).
Following data linkage, the data were anonymised by replacing the
CHI number with a unique study number.
Statistical analysis. The influence of characteristics of 20-year-old
women on their likelihood of attending for screening was estimated
through logistic regression, with a log link. The unadjusted and
adjusted risk ratios of attendance by year of birth cohort, SIMD,
number of vaccine doses (0–3) and rurality were estimated. The
primary data analysis was based upon all women resident in
Scotland at age 20 years and who were eligible for invitation to
screening. We analysed attendance at screening over the
subsequent 12 months so that all women had the same time
opportunity to attend for screening. In a secondary analysis, we
investigated the effect of age on attendance for first screen by
devising a time-dependent analysis to properly account for the
length of time that the earlier cohorts have to attend for screening
compared with the younger cohorts. The results from this analysis
were indistinguishable for the primary one, and so are not
presented. In a sensitivity analysis, we analysed only those who
were eligible for vaccination, that is, born after September 1990.
Potential interactions between the birth cohort and the number
of doses, and between number of doses and deprivation, on the
uptake of screening were explored. As none of the interactions
were prespecified, we use a Bonferroni adjustment in model
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selection. For the dose and deprivation interaction, further
stratification was conducted to compare the uptake rates split by
those eligible for the catch-up vaccination campaign and those not.
All statistical modelling was conducted in IBM SPSS Statistics
version 15 (Chicago, IL, USA) and graphics produced in Microsoft
Excel (Microsoft Corporation, Seattle, WA, USA).
RESULTS
Study population. A total of 201 023 women were identified of
whom 94 460 (47%) had attended for screening within 12 months
of their 20th birthday. The demographic characteristics of all
women are shown in Table 1.
Uptake, birth cohort, SIMD, immunisation and rurality. Both
unadjusted and adjusted analysis (Table 1) showed significant
association between uptake and year of birth, SIMD, immunisation
status and rurality (all Po0.05).There was a significant decline in
overall attendance from the 1988 cohort to the 1993 cohort with
the adjusted attendance ratio for those in the 1988 cohort being
1.49 times (95% CI 1.46–1.52) that of the 1993 cohort.
Immunisation compensated for this decrease in uptake with
unvaccinated individuals having a reduced ratio of attendance
compared with those fully vaccinated (RR¼ 0.65, 95% CI 0.64–
0.65) (Table 1); however, the downward trend with the later birth
cohorts persisted in those fully vaccinated (Figure 1). Attendance
for screening decreased from baseline in the unvaccinated group
after the introduction of immunisation compared with the 1988
and 1989 cohorts, who were almost all unimmunised, although
there is a suggestion of a levelling off in those born in 1993. Among
those vaccinated, there is a clear trend of increased proportions
attending with increasing number of doses, though in all groups
there is a downward trend over time.
The relationship between deprivation and screening attendance
showed the lowest uptake in the least deprived individuals
(Table 1) with statistically significant increased risk of attendance
in all SIMD quintiles compared with the least deprived, although
the scale of the increase is relatively small (adjusted RRB1.05 in all
other SIMD groups).
Interactions. The most important interactions involved year of birth,
SIMD and the number of doses of vaccine, all with Po0.001. There is
an interaction between urban/rural status and SIMD (P¼ 0.002), which
is characterised by low screening attendance percentage for those in the
least deprived groups in very remote areas. The other interactions
involving the urban/rural status were not important.
Examination of the interaction between SIMD and vaccination
status (Table 2) showed that unimmunised women in SIMD5 (least
deprived) were also least likely to attend for screening. This was
seen in all year of birth cohorts (Figure 2). Figure 2 also shows that
the difference in uptake between the SIMD quintiles is widening in
the younger cohorts of unimmunised women. Whereas women in
SIMD1–4 born in 1988 and 1989 showed a trend of increasing
attendance with decreasing deprivation, there was no consistent
effect of SIMD on attendance from 1990 onwards. Uptake was
however always lowest in the least deprived group (SIMD5).
In those immunised during the catch-up vaccination campaign
(Figure 3), full immunisation was associated with higher uptake of
screening across all SIMD quintiles compared with partial
immunisation. The deprivation differential is minimal among
women who received one, two or three doses of the vaccine
(Figure 3), with no clear trend discernible (P¼ 0.134).
DISCUSSION
Immunisation against HPV with the bivalent vaccine is associated
with a higher uptake of the first smear at age 20 years. The women
Table 1. Demographics of women born between 1 January 1988 and September 1993 invited for screening
Univariate Multivariate -all women
Multivariate -eligible for
HPV vaccination (1990
onwards) only
No. of
women
Attendance
%
Risk ratio 95% CI Risk ratio 95% CI Risk ratio 95% CI
Year of birth
1988 34506 48.7 1.100 1.081–1.119 1.494 1.464–1.524 – –
1989 33886 47.7 1.077 1.059–1.097 1.462 1.433–1.492 – –
1990 35333 47.5 1.073 1.055–1.092 1.330 1.306–1.354 1.201 1.172–1.231
1991 35510 47.7 1.077 1.058–1.096 1.111 1.092–1.130 1.115 1.096–1.134
1992 35578 45.6 1.029 1.011–1.048 1.019 1.001–1.037 1.018 1.000–1.035
1993 26210 44.3 1 1 1
Doses of vaccine
0 128629 43.6 0.807 0.799–0.815 0.645 0.637–0.654 0.592 0.582–0.602
1 3285 44 0.815 0.784–0.848 0.791 0.761–0.822 0.796 0.765–0.829
2 6343 48.1 0.891 0.868–0.915 0.863 0.841–0.886 0.891 0.845–0.893
3 54 1 1 1
SIMD
1 (Most deprived) 45 007 46.4 1.038 1.023–1.054 1.040 1.025–1.055 1.039 1.019–1.060
2 41655 47.6 1.064 1.049–1.080 1.058 1.043–1.073 1.045 1.025–1.067
3 38969 47.5 1.062 1.047–1.078 1.049 1.034–1.065 1.034 1.013–1.056
4 34243 49.1 1.097 1.080–1.114 1.070 1.054–1.086 1.044 1.023–1.066
5 (Least deprived) 41 149 44.7 1 1 1
Urban rural
Urban 187191 46.8 1.003 0.975–1.031 1.019 0.991–1.048 0.988 0.951–1.026
Accessible remote 8142 51.5 1.104 1.066–1.143 1.087 1.051–1.125 1.027 0.980–1.076
Very remote 5690 46.7 1 1 1
Abbreviations: CI¼ confidence interval; SIMD¼ Scottish Index of Multiple Deprivation.
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subject to analysis had been eligible for the HPV vaccine as part of
the catch-up cohort following the introduction of the HPV
immunisation programme in Scotland, in September 2008. As the
increased uptake was observed with any number of doses received,
it may reflect characteristics of the women taking up the
opportunity for immunisation, in particular their willingness to
take responsibility for their own health. These results are
encouraging for cervical screening of immunised populations in
view of concerns of a hypothetical reduction in participation in
screening and corroborate the effect previously reported from
Wales (Beer et al, 2014). It is also consistent with the increased
uptake reported in the United States and Sweden (Herweijer et al,
2015; Paynter et al, 2015; Sauer et al, 2015). The intention to
participate in screening reported in the United States, Australia
and Scotland appears to have been realised (Paul-Ebhohimhen
et al, 2010; Price et al, 2011; Brotherton and Mullins, 2012).
Although immunisation is associated with an increased uptake of
screening, the downward trend in uptake over the 6 year-cohorts
remains. This is worrying for screening as a process. Many factors
affect the uptake of cervical screening, including age, individual
perception of risk and external influences, such as media coverage
and celebrity involvement(Moser et al, 2009; Waller et al, 2012).
Deprivation is usually associated with decreased uptake of cervical
screening, so the level of uptake in the least deprived quintile,
observed in all unimmunised women, is both unexpected and
unwelcome. The reasons for this are not clear, but it has been a
feature of Scottish cervical screening for some years. It could relate
to reduced usage of health services in this group of women when
compared with the more deprived quintiles, or to population
movements as a result of entering higher education or migration
from areas with no linkage of immunisation to screening. Access to
opportunistic screening is possible in Scotland, although minimal
especially in young women with access to free health care. Ferris and
colleagues report an intriguing observation that those who default
from screening are more likely to take up immunisation because it
will extend screening intervals (Ferris et al, 2012). Whether, having
taken up immunisation, the women then will attend for screening is
not reported, but our data would indicate that immunised women
are more likely to attend.
Immunisation rates in the catch-up cohorts were related to
deprivation, with a 5% reduction in vaccine uptake in the most
deprived quintile compared with the least deprived (Sinka et al,
2014). A similar trend in uptake of screening was not observed in
the immunised cohorts, suggesting that being immunised has a
more motivating effect on more deprived women than on more
affluent women. Until there is a better understanding of the
reasons for the poor uptake in the unimmunised and most affluent
women, it is difficult to explain the relationship between uptake of
screening and immunisation in this group. The uptake rates in
unimmunised women are, however, strikingly low and this group
should be considered for further public health intervention.
Close attention was paid to publicity about HPV immunisation
and the relationship between HPV, cervical disease and screening
during the immunisation campaign in 2008. The information given
to young girls and their parents continues to stress the need for
continued screening despite being immunised. The campaign was
many-pronged, with advertisements on television and in cinemas,
as well as written information provided to the girls and their
parents directly (Potts et al, 2013). The national screening leaflet
for women invited for their first screening test has a section aimed
at women who have been vaccinated to highlight the need for
vaccinated women to attend for screening. This would appear to
have been an effective strategy and suggests that, if appropriate
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Figure 1. The proportion of women aged 20 attending for the first
screen within 12 months by year of birth and number of doses of
vaccine. Note those born before 1990 were not eligible for HPV
vaccination.
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Figure 2. The proportion of unvaccinated women aged 20 attending for
first screen within 12 months by year of birth and SIMD.Note those born
before 1990 were not eligible for routine HPV vaccination and the
whole cohort is represented here. In the post-1990 cohorts, vaccine
was offered and unvaccinated women chose not to receive the vaccine.
Table 2. Screening attendance proportions by SIMD and
number of vaccine doses for women born between 1 January
1988 and September 1993 and invited for screening
Vaccine
dose SIMD
Total
eligible Attended
%
Uptake
0 1 29 983 13168 43.9
2 26 815 11945 44.5
3 24 548 10791 44
4 20 796 9598 46.2
5 26 487 10562 39.9
1 1 1106 483 43.7
2 811 337 41.6
3 584 276 47.3
4 440 187 42.5
5 344 163 47.4
2 1 1908 914 47.9
2 1478 696 47.1
3 1187 590 49.7
4 944 456 48.3
5 826 396 47.9
3 1 12 010 6338 52.8
2 12 551 6853 54.6
3 12 650 6862 54.2
4 12 063 6559 54.4
5 13 492 7286 54
2 01 023 94460 47.6
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information is given to women at the time of immunisation and
when invited for screening, there is an appreciation that
immunisation does not confer complete protection from cervical
cancer and that screening is still necessary.
However, from April 2016, the age at which young women will
be screened in Scotland will increase to 25. Furthermore, in
September 2014, the Joint Committee for Vaccination and
Immunisation suggested that girls as young as 11 could be offered
the HPV vaccine. Consequently, there will be a significant period
of time (13 years) between immunisation and invitation for the
first screen; therefore, it is critical that regular educational messages
are communicated to young women in order to sustain the
reduction in cervical disease.
The strengths of this study are that it uses data routinely entered
into SCCRS at a national level for the management of women in
the Scottish Cervical Screening Programme. Results are entered
contemporaneously and are available for any screening episode
within Scotland. Data quality is actively managed through the
programme. The CHI number allows direct and robust linkage of
many aspects of an individual’s health record. The use of a national
screening database means that the sample size is substantially
larger than most previous studies. Although the Swedish study of
Herweijer and colleagues was larger overall, there were significantly
fewer immunised women (Herweijer et al, 2015).
One of the main limitations of this study is that the women
analysed may be a different population, with different motivation,
from women immunised routinely at age 12 or 13. Paynter et al
have reported that although uptake in recently immunised women
is better than unimmunised women of the same age, this effect
diminishes as the time between immunisation and eligibility for
cervical screening increases (Paynter et al, 2015). Although such a
trend is not apparent in this analysis, these results may not
be generalisable to all immunised populations. The analysis will
therefore need to be repeated when routinely immunised women
from the school-based programme enter the Scottish Cervical
Screening Programme from September 2015. Other limitations are
that the observational nature of this study means we are unable
to account for possible confounding due to variation in uptake of
vaccination and of screening by factors such as school attendance,
educational attainment and employment. The very high uptake of
immunisation in Scotland means that the numbers of partially
immunised women are small, and thus the confidence limits for
those women vaccinated with one and two doses are wide. Further
work includes extending these observations to include routinely
immunised women. Our results look only at the first invitation to
screening and it is important to examine the attendance at second
and subsequent routine screens. The comprehensive nature of the
SCCRS database makes this eminently possible.
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